BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8020515)

  • 1. Pharmacokinetics and tissue distribution of iomeprol in animals.
    Lorusso V; Luzzani F; Bertani F; Tirone P; de Haën C
    Eur J Radiol; 1994 May; 18 Suppl 1():S13-20. PubMed ID: 8020515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical safety assessment of iomeprol for injection as contrast medium for myelography.
    La Noce A; Bertani F; Lorusso V; Luzzani F; Tirone P; de Haën C
    Eur J Radiol; 1994 May; 18 Suppl 1():S43-50. PubMed ID: 8020518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic effects of iomeprol for injection in experimental animals.
    Cipolla P; Tirone P; Luzzani F; de Haën C
    Eur J Radiol; 1994 May; 18 Suppl 1():S32-42. PubMed ID: 8020517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicological safety assessment of iomeprol, a new X-ray contrast agent.
    Morisetti A; Tirone P; Luzzani F; de Haën C
    Eur J Radiol; 1994 May; 18 Suppl 1():S21-31. PubMed ID: 8020516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and tissue distribution in animals of gadobenate ion, the magnetic resonance imaging contrast enhancing component of gadobenate dimeglumine 0.5 M solution for injection (MultiHance).
    Lorusso V; Arbughi T; Tirone P; de Haën C
    J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S181-94. PubMed ID: 10608414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of acute renal failure on the distribution of iomeprol, a nonionic contrast agent, to cerebrospinal fluid in rats.
    Hagino M; Yamamoto K; Ohashi K; Sueda T; Kotaki H; Hayashi M; Sawada Y; Iga T
    Biol Pharm Bull; 1997 Aug; 20(8):939-42. PubMed ID: 9300148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain penetration of intrathecal iomeprol in dogs.
    La Noce A; Lorenzon P; Pugliese F; Pellecchi G; Orlandini I; Tirone P
    Acta Radiol; 1996 Jul; 37(4):578-81. PubMed ID: 8688246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and pharmacokinetics of a new liposomal liver-specific contrast agent for CT: results of clinical testing in nonpatient volunteers.
    Spinazzi A; Ceriati S; Pianezzola P; Lorusso V; Luzzani F; Fouillet X; Alvino S; Rummeny EJ
    Invest Radiol; 2000 Jan; 35(1):1-7. PubMed ID: 10639031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacology of iomeprol.
    Rosati G
    Eur J Radiol; 1994 May; 18 Suppl 1():S51-60. PubMed ID: 8020519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys.
    Matsumoto S; Tagawa M; Amejima H; Nakao M; Kagemoto A; Fujii T; Miyazaki H; Sekine Y
    Arzneimittelforschung; 1993 Oct; 43(10):1084-94. PubMed ID: 8267675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urine viscosity after injections of iotrolan or iomeprol.
    Ueda J; Furukawa T; Higashino K; Takahashi S; Araki Y; Kubo K; Nakashima T
    Acta Radiol; 1997 Nov; 38(6):1079-82. PubMed ID: 9394674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and safety of iomeprol in healthy volunteers and in patients with renal impairment or end-stage renal disease requiring hemodialysis.
    Lorusso V; Taroni P; Alvino S; Spinazzi A
    Invest Radiol; 2001 Jun; 36(6):309-16. PubMed ID: 11410750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iomeprol: a review of its use as a contrast medium.
    Dooley M; Jarvis B
    Drugs; 2000 May; 59(5):1169-86. PubMed ID: 10852647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma pharmacokinetics, tissue distribution and excretion of MnDPDP in the rat and dog after intravenous administration.
    Hustvedt SO; Grant D; Southon TE; Zech K
    Acta Radiol; 1997 Jul; 38(4 Pt 2):690-9. PubMed ID: 9245964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man.
    Ahr HJ; Boberg M; Brendel E; Krause HP; Steinke W
    Arzneimittelforschung; 1997 Jun; 47(6):734-45. PubMed ID: 9239452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of the new thyrotropin releasing hormone analogue montirelin hydrate. 1st communication: plasma concentrations, metabolism and excretion after a single intravenous administration to rats, dogs and monkeys.
    Sugimoto T; Hayashi T; Okita A; Morino A
    Arzneimittelforschung; 1996 Feb; 46(2):106-13. PubMed ID: 8720298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and whole-body distribution of the new chemotherapeutic agent beta-D-glucosylisophosphoramide mustard and its effects on the incorporation of [methyl-3H]-thymidine in various tissues of the rat.
    Stüben J; Port R; Bertram B; Bollow U; Hull WE; Schaper M; Pohl J; Wiessler M
    Cancer Chemother Pharmacol; 1996; 38(4):355-65. PubMed ID: 8674159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absorption, distribution, metabolism and excretion of [14C]ebastine after a single administration in rats.
    Fujii T; Matsumoto S; Amejima H; Hatoyama T; Nakao M; Kagemoto A; Tanaka K; Miyazaki H
    Arzneimittelforschung; 1994 Apr; 44(4):527-38. PubMed ID: 7912071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic profile of iobitridol.
    Dencausse A; Violas X; Feldman H; Havard P; Chambon C
    Acta Radiol Suppl; 1996; 400():25-34. PubMed ID: 8619349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of the new thyrotropin releasing hormone analogue montirelin hydrate. 2nd communication: distribution and transfer into the fetus and milk after a single intravenous administration and pharmacokinetics and enzyme induction after repeated intravenous administration to rats.
    Sugimoto T; Hayashi T; Okita A; Morino A
    Arzneimittelforschung; 1996 Feb; 46(2):114-27. PubMed ID: 8720299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.